Nilotinib: the other phase II trial

posted Aug 3, 2017, 8:07 AM by Missoula PDSG

This article describes how nilotinib, a drug approved by the FDA for treatment of leukemia, may be an effective and potentially disease modifying  treatment for Parkinson's Disease based on animal studies and a phase I trial in humans.  The drug is now entering phase II clinical trials.

Comments